Active substances
Ferrous sulfate + Folic acid
- SFDA 6
- US FDA 1
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FERRO-FOL CAPSULE | 150,0.5 mg,mg | Capsule · Oral use | 30 Blister | SAR 8.40 | Generic · OTC | EIPICO | Valid |
| FOLICRON SR CAPSULE | 150,0.5 mg,mg | Sustained-release tablet · Oral use | 30 Blister | SAR 7.00 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid |
| FEFOL SPANSULES | 150,0.5 mg,mg | Capsule · Oral use | 30 Blister | SAR 8.60 | Generic · OTC | MEDA AB | Withdrawn by MAH · Not Marketed |
| FEFOL SPANSULES | 150, 0.5 mg | Capsule · Oral use | 30 Blister | SAR 8.60 | Generic · OTC | I.C.N.PHARMACEUTICALS | Withdrawn by MAH · Not Marketed |
| FERAL CAPS | 150, 0.5 mg | Capsule · Oral use | 30 Blister | SAR 7.25 | Generic · OTC | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| FERROGRAD-FOLIC TAB | 325, 350 mg | Tablet · Oral use | 30 Blister | SAR 9.10 | NCE · OTC | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
BARIATRIC SURGERY; IRON DEFICIENCY ANEMIA; MATERNAL AND CHILD HEALTHCARE- SUPPLEMENTATION FOR MOTHER AND CHILD
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| FOLVRON | 182MG;0.33MG | capsule · oral | LEDERLE | Discontinued | 13 Aug 1946 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Ferrous sulfate 325mg / Folic acid 350microgram modified-release tablets | £2.64 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.